Business

Announcement on Voluntary Disclosure of Iza-Bren (EGFR×HER3 Bispecific ADC) Receiving Breakthrough Therapy Designation from the U.S. FDA for the Treatment of Advanced EGFR-Mutant Non-Small Cell Lung Cancer

Announcement on Voluntary Disclosure of Iza-Bren (EGFR×HER3 Bispecific ADC) Receiving Breakthrough Therapy Designation from the U.S. FDA for the Treatment of Advanced EGFR-Mutant Non-Small Cell Lung Cancer

articleSichuan Biokin Pharmaceutical Co., Ltd. Class AAugust 18, 20253/news/announcement-on-voluntary-disclosure-of-iza-bren-egfrher3-bispecific-adc-receiving-breakthrough-therapy-designation-from-the-us-fda-for-the-treatment-of-advanced-egfr-mutant-non-small-cell-lung-cancer
Announcement on Voluntary Disclosure of Iza-Bren (EGFR×HER3 Bispecific ADC) Receiving Breakthrough Therapy Designation from the U.S. FDA for the Treatment of Advanced EGFR-Mutant Non-Small Cell Lung Cancer

About this update from Sichuan Biokin Pharmaceutical Co., Ltd. Class A

Announcement on Voluntary Disclosure of Iza-Bren (EGFR×HER3 Bispecific ADC) Receiving Breakthrough Therapy Designation from the U.S. FDA for the Treatment of Advanced EGFR-Mutant Non-Small Cell Lung CancerThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Sichuan Biokin Pharmaceutical Co., Ltd. Class A